Literature DB >> 3025330

Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts.

D M Mosser, H Vlassara, P J Edelson, A Cerami.   

Abstract

In this paper we demonstrate the involvement of the macrophage receptor for advanced glycosylation endproducts (AGE) in the phagocytosis of Leishmania major promastigotes. Blocking of this receptor with the ligand, AGE-BSA, leads to a 50% decrease in phagocytosis relative to controls, and a comparable decrease in the respiratory burst. The inhibition of phagocytosis by AGE-BSA was specific to leishmania. The binding of zymosan or C3bi-RBC and the phagocytosis of IgG-RBC or latex beads was not affected by the presence of AGE-BSA. Blocking of both the AGE receptor and CR3 decreases leishmania binding by nearly 90%, and reduces the respiratory burst by 80%, indicating that the two receptors account for the bulk of L. tropica promastigote recognition and uptake by the macrophage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3025330      PMCID: PMC2188265          DOI: 10.1084/jem.165.1.140

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  A model in mice for experimental leishmaniasis with a West African strain of Leishmania tropica.

Authors:  B Bjorvatn; F A Neva
Journal:  Am J Trop Med Hyg       Date:  1979-05       Impact factor: 2.345

2.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

Review 3.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

4.  Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes.

Authors:  R D Pearson; R T Steigbigel
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

5.  Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose.

Authors:  S Pongor; P C Ulrich; F A Bencsath; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

6.  Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.

Authors:  D M Mosser; P J Edelson
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

7.  The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes.

Authors:  D M Mosser; P J Edelson
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.

Authors:  J M Blackwell; R A Ezekowitz; M B Roberts; J Y Channon; R B Sim; S Gordon
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

  10 in total
  19 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

2.  Attachment of Blastomyces dermatitidis conidia to murine bronchoalveolar macrophages: characterization of binding and elicitation of respiratory burst.

Authors:  A M Sugar; M Picard
Journal:  Antonie Van Leeuwenhoek       Date:  1990-01       Impact factor: 2.271

3.  Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes.

Authors:  M E Wilson; R D Pearson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

Review 4.  Redundant and regulatory roles for Toll-like receptors in Leishmania infection.

Authors:  P Chauhan; D Shukla; D Chattopadhyay; B Saha
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

5.  Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors.

Authors:  Helmut Laufs; Kerstin Müller; Jens Fleischer; Norbert Reiling; Nicole Jahnke; Jens C Jensenius; Werner Solbach; Tamás Laskay
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Lipophosphoglycan blocks attachment of Leishmania major amastigotes to macrophages.

Authors:  M Kelleher; S F Moody; P Mirabile; A H Osborn; A Bacic; E Handman
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages.

Authors:  L Proudfoot; A V Nikolaev; G J Feng; W Q Wei; M A Ferguson; J S Brimacombe; F Y Liew
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Differences in human macrophage receptor usage, lysosomal fusion kinetics and survival between logarithmic and metacyclic Leishmania infantum chagasi promastigotes.

Authors:  Norikiyo Ueno; Carol L Bratt; Nilda E Rodriguez; Mary E Wilson
Journal:  Cell Microbiol       Date:  2009-08-20       Impact factor: 3.715

9.  Identification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotes.

Authors:  M Kelleher; A Bacic; E Handman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  Comparison of receptors required for entry of Leishmania major amastigotes into macrophages.

Authors:  R A Guy; M Belosevic
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.